1.
Argos Therapeutics John N. Bonfiglio, Ph.D. Argos Therapeutics, Director .... UK, where she studied erythromycin biosynthesis with Drs. James Staunton and Peter Leadlay. ...
2.
Argos Therapeutics Mar 6, 2009 ... Developing therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Includes pipeline for monoclonal for lupus, ...
3.
Argos Therapeutics Mar 6, 2009 ... Developing therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Includes pipeline for monoclonal for lupus, ...
4.
Argos Therapeutics Mar 6, 2009 ... Developing therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Includes pipeline for monoclonal for lupus, ...
5.
Argos Therapeutics Mar 6, 2009 ... Developing therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Includes pipeline for monoclonal for lupus, ...
6.
Argos Therapeutics Mar 6, 2009 ... Developing therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Includes pipeline for monoclonal for lupus, ...
7.
Argos Therapeutics Mar 6, 2009 ... Developing therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Includes pipeline for monoclonal for lupus, ...
8.
Argos Therapeutics Timothy Trost joined Argos Therapeutics in 2002. Prior to joining Argos, Mr. Trost most recently served as Senior Vice President & Chief Financial Officer ...
9.
Argos Therapeutics Mar 6, 2009 ... Developing therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Includes pipeline for monoclonal for lupus, ...
10.
Argos Therapeutics Under the terms of the agreement, Argos will receive up to $69 million comprised of up front and milestone payments, in addition to royalties on potential ...
|
|
View More »
|